{
    "clinical_study": {
        "@rank": "127564", 
        "arm_group": [
            {
                "arm_group_label": "GDPT regimen", 
                "arm_group_type": "Experimental", 
                "description": "GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen"
            }, 
            {
                "arm_group_label": "CHOP regimen", 
                "arm_group_type": "Experimental", 
                "description": "CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of GDPT regiment\n      (gemcitabine\uff0ccisplatin,Prednisone ,Thalidomide\n\n      ) for patients with Peripheral T-cell lymphoma."
        }, 
        "brief_title": "Treatment of Peripheral T-cell Lymphoma", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral T-cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Peripheral"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with Peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot\n      be treated successfully with the conventional chemotherapy of CHOP. The investigators have\n      been proceeding this trial to evaluate the efficacy and safety of the combination\n      chemotherapy regiment GDPT regiment (gemcitabine\uff0ccisplatin,Prednisone ,Thalidomide\n\n      ) in the patients with Peripheral T-cell lymphoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time > 3 months\n        Histological confirmed Peripheral T cell lymphoma None of chemotherapy or radiotherapy has\n        been previously used None of chemotherapy contraindication: hemoglobin \u2265 90 g/dl,\n        neutrophil \u2265 1.5\u00d7109/L, platelet \u2265 100\u00d7109/L, ALT and AST \u2264 2\u00d7ULN, serum bilirubin \u2264\n        1.5\u00d7ULN, serum creatine \u2264 1.5\u00d7upper limitation of normal (ULN), Serum Albumin \u2265 30g/L,\n        serum plasminogen is normal (Inclusion Criteria of 1,3,6 groups ) At least one measurable\n        lesion None of other serious diseases, cardiopulmonary function is normal Pregnancy test\n        of women at reproductive age must be negative Patients could be followed up None of other\n        relative treatments including the traditional Chinese medicine, immunotherapy,biotherapy\n        except anti-bone metastasis therapy and other symptomatic treatments.\n\n        volunteers who signed informed consent.\n\n        Exclusion Criteria:\n\n        Disagreement on blood sample collection Patients allergic of any of drug in this regimen\n        or with metabolic disorder Pregnant or lactating women Serious medical illness likely to\n        interfere with participation Serious infection Primitive or secondary tumors of central\n        nervous system Chemotherapy or radiotherapy contraindication The evidence of CNS\n        metastasis History of peripheral nervous disorder or dysphrenia patients participating in\n        other clinical trials patients taking other antitumor drugs patients estimated to be\n        unsuitable by investigato"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "14 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664975", 
            "org_study_id": "hnslblzlzx2011-3"
        }, 
        "intervention": [
            {
                "arm_group_label": "GDPT regimen", 
                "description": "GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt\uff08intravenously guttae\uff09,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.", 
                "intervention_name": "GDPT regimen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CHOP regimen", 
                "description": "CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.", 
                "intervention_name": "CHOP regimen", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin", 
                "Cyclophosphamide", 
                "Prednisone", 
                "Thalidomide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Peripheral T-cell lymphoma;chemotherapy;", 
            "RR;PFS;OS"
        ], 
        "lastchanged_date": "September 19, 2013", 
        "location": {
            "contact": {
                "email": "mingzhi_zhang@126.com", 
                "last_name": "Mingzhi Zhang, Pro,Dr", 
                "phone": "13838565629"
            }, 
            "facility": {
                "address": {
                    "city": "Zhengzhou", 
                    "country": "China", 
                    "state": "Henan", 
                    "zip": "450052"
                }, 
                "name": "Oncology Department of The First Affiliated Hospital of Zhengzhou University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide )", 
        "overall_contact": {
            "email": "Mingzhi_zhang@126.com", 
            "last_name": "Mingzhi zhang, Pro\uff0cDr", 
            "phone": "13838565629"
        }, 
        "overall_official": {
            "affiliation": "The First Affiliated Hospital of Zhengzhou University", 
            "last_name": "Mingzhi Zhang, Pro,Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "up to end of follow-up-phase (approximately 24 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664975"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhengzhou University", 
            "investigator_full_name": "Mingzhi Zhang", 
            "investigator_title": "the director of oncology department of the first affiliated hospital", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles", 
                "measure": "response rate", 
                "safety_issue": "No", 
                "time_frame": "every 6 weeks,up to completion of treatment(approximately 18 weeks )"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to the date of death (approximately 5 years)"
            }, 
            {
                "measure": "median survival time", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Zhengzhou University", 
        "sponsors": {
            "collaborator": {
                "agency": "Zhengzhou University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Mingzhi Zhang", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}